Quantcast
Last updated on April 17, 2014 at 12:30 EDT

Latest Anthracyclines Stories

2014-03-19 08:29:44

New Investment Will Fund the Company's Upcoming Phase 2 Clinical Trial in Sarcoma Patients BIRMINGHAM, Ala., March 19, 2014 /PRNewswire/ -- Gem Pharmaceuticals announced today that current Gem boardmembers/investors Diane Hendricks and Karl Leo have agreed to provide up to $4.5 million in new capital in order to fund the Company's upcoming Phase 2 clinical trial of GPX-150 in sarcoma patients. These funds will be invested over the course of the trial. Photo -...

2014-02-04 08:34:07

QUÉBEC CITY, Feb. 4, 2014 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZ) (the "Company") today announced that an article on Phase 2 results for zoptarelin doxorubicin (AEZS-108) in endometrial cancer has been published in the February issue of the International Journal of Gynecological Cancer. Zoptarelin doxorubicin, is the Company's cytotoxic peptide conjugate which specifically targets luteinizing hormone-releasing hormone ("LHRH") receptors. The article,...

2014-02-03 08:27:19

QUÉBEC CITY, Feb. 3, 2014 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZ) (the "Company") today announced that presentations on two of its oncology compounds, zoptarelin doxorubicin (AEZS-108) and disorazol Z, will be made during the 11(th) International Symposium on GnRH, in Salzburg, Austria, February 9 -11, 2014. The session will be held on Tuesday, February 11, 2014, in Hall A of the Wyndham Hotel in Salzburg. Presentations are scheduled as follows:...

2013-11-13 13:23:44

Phase III trial examines pathological complete response rate Giving trastuzumab and anthracyclines at the same time is effective at treating HER-2-positive breast cancer, but there is concern that this combination can be associated with an increased risk of cardiac toxicity. New research from Aman Buzdar M.D., professor and vice president of clinical research at The University of Texas MD Anderson Cancer Center, and colleagues in the Alliance for Clinical Trials in Oncology, shows these...

2013-08-08 16:28:07

All amounts are in U.S. dollars (unless otherwise noted) QUEBEC CITY, Aug. 8, 2013 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZ) (the "Company"), a specialty biopharmaceutical company engaged in developing novel treatments in oncology and endocrinology, today reported financial and operating results as at and for the second quarter ended June 30, 2013. Key Highlights Appointment of New President and CEO -- David Dodd was appointed President...

2013-07-31 08:29:25

All amounts are in U.S. dollars (unless otherwise noted) QUÉBEC CITY, July 31, 2013 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZ) (the "Company") today announced that the first patient has been recruited and dosed for the Phase 3 ZoptEC (Zoptarelin doxorubicin in Endometrial Cancer) trial in women with endometrial cancer resistant to platinum/taxane-based chemotherapy. "We have reached another important milestone in the final clinical development stage for...

2013-06-03 08:29:46

QUÉBEC CITY, June 3, 2013 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZ) (the "Company") today announced that final data for the Phase 1 portion of the ongoing Phase 1/2 trial with its lead oncology compound, zoptarelin doxorubicin (AEZS-108), demonstrated the compound's promising anti-tumor activity in heavily pre-treated men with castration- and taxane-resistant prostate cancer. Results were presented earlier today by lead investigator, Jacek...

2013-06-03 08:29:35

Data Support Ongoing Phase 2 Study in Platinum Resistant Ovarian Cancer SEATTLE, June 3, 2013 /PRNewswire/ -- VentiRx Pharmaceuticals, Inc. in collaboration with the Gynecologic Oncology Group and the National Cancer Institute's Cancer Therapy Evaluation Program announced today that positive preclinical and clinical data of VTX-2337 in combination with Doxil(® )(pegylated liposomal doxorubicin) or paclitaxel in women with recurrent ovarian cancer were presented at the American...

2013-05-23 12:26:45

WASHINGTON, May 23, 2013 /PRNewswire-USNewswire/ -- Treating pediatric leukemia patients with a liposomal formulation of anthracycline-based chemotherapy at a more intense-than-standard dose during initial treatment may result in high survival rates without causing any added heart toxicity, according to the results of a study published online today in Blood, the Journal of the American Society of Hematology (ASH). Acute myeloid leukemia (AML), the second most common form of leukemia in...

2013-02-05 20:21:09

LAWRENCEVILLE, N.J., Feb. 5, 2013 /PRNewswire/ -- Celsion Corporation (NASDAQ: CLSN) today announced that Zheijang HISUN Pharmaceutical Company (HISUN) does not plan to pursue the exclusive option to license ThermoDox® for the Greater China market. Accordingly, the parties will not enter into the exclusive license agreement, and Celsion will not receive nor will it require any future payment for the option or license, as contemplated in the Exclusive Option Agreement announced on January...